Want to see AU:S66 full AI Analyst Report?
Top Page
Star Combo Pharma Ltd.
(Sydney:S66)
Select Model
Select Model
Rating:69Neutral
Price Target:
AU$0.15
▲(9.29% Upside)
Action:Reiterated
Date:08/26/26
The score is driven by attractive valuation (low P/E and dividend yield) and a solid balance-sheet foundation with improving cash flow. Offsetting these positives are weak and volatile recent fundamentals (sharp 2026 revenue and margin deterioration) and momentum indicators that look stretched despite a near-term uptrend.
Positive Factors
Conservative Balance Sheet
Low leverage and substantial equity provide financial resilience through uneven earnings periods. This reduces balance-sheet stress, preserves flexibility to fund operations, and gives the company a stronger buffer than a highly debt-funded peer during weaker trading conditions.
Negative Factors
Sharp Revenue Contraction
A substantial revenue decline weakens operating leverage and makes future margin recovery more difficult. If the contraction reflects persistent demand or distribution problems rather than a temporary fluctuation, it could reduce the scale and competitiveness of the business over coming periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and substantial equity provide financial resilience through uneven earnings periods. This reduces balance-sheet stress, preserves flexibility to fund operations, and gives the company a stronger buffer than a highly debt-funded peer during weaker trading conditions.
Read all positive factors
Star Combo Pharma Ltd. (S66) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.90M
Dividend Yield2.64%
Average Volume (3M)26.82K
Price to Earnings (P/E)48.3
Beta (1Y)-0.68
Revenue Growth-15.24%
EPS Growth-92.54%
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)<0.01
Shares Outstanding135,002,980
10 Day Avg. Volume31,289
30 Day Avg. Volume26,815
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)0.47
Price to Sales (P/S)0.77
P/FCF Ratio22.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Star Combo Pharma Ltd. Business Overview & Revenue Model
Company Description
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages th...
Star Combo Pharma Ltd. Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
78
Positive
Cash Flow
63
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.57M | 27.81M | 26.02M | 24.70M | 22.88M |
| Gross Profit | 4.99M | 6.27M | 5.44M | 4.66M | 5.61M |
| EBITDA | 1.24M | 6.64M | 2.79M | -2.53M | -126.71K |
| Net Income | 394.61K | 5.25M | 747.33K | -4.00M | -696.35K |
Balance Sheet | |||||
| Total Assets | 50.11M | 48.45M | 42.82M | 42.23M | 43.44M |
| Cash, Cash Equivalents and Short-Term Investments | 18.01M | 18.11M | 7.36M | 9.49M | 10.39M |
| Total Debt | 4.19M | 3.93M | 4.03M | 4.19M | 4.12M |
| Total Liabilities | 11.28M | 10.19M | 9.30M | 8.97M | 8.04M |
| Stockholders Equity | 38.83M | 38.08M | 33.32M | 33.09M | 35.41M |
Cash Flow | |||||
| Free Cash Flow | 822.64K | 11.55M | -1.76M | -851.83K | -7.21M |
| Operating Cash Flow | 3.28M | 11.94M | -316.45K | 1.88M | 87.11K |
| Investing Cash Flow | -2.02M | -9.72M | -136.79K | -3.23M | -3.24M |
| Financing Cash Flow | -940.75K | -795.12K | -370.93K | -53.44K | -169.08K |
Star Combo Pharma Ltd. Technical Analysis
Neutral
0.14
Price Trends
0.13
Positive
0.15
Negative
0.19
Negative
Market Momentum
<0.01
Negative
66.05
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Neutral. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and below the 200-day MA of 0.19, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.05 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:S66.
Star Combo Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$18.90M | 48.28 | 1.02% | 2.64% | -15.24% | -92.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$13.33M | -1.79 | -88.51% | ― | 11.96% | -81.99% | |
44 Neutral | AU$5.28M | -2.34 | -49.07% | ― | -33.53% | 42.98% | |
41 Neutral | AU$1.61M | -0.38 | -239.37% | ― | ― | ― | |
39 Underperform | AU$16.92M | -5.29 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$6.99M | -0.01 | 226.76% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:S66
Star Combo Pharma Ltd.
0.14
-0.07
-33.33%
AU:EVE
EVE Health Group Limited
0.02
-0.02
-50.00%
AU:NUC
Nuchev Pty Ltd
0.09
-0.06
-43.33%
AU:HCT
Holista Colltech Limited
0.05
-0.06
-56.19%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
16.67%
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
Star Combo Pharma Ltd. Corporate Events
Star Combo Pharma Declares Dividend for Year Ended June 2026
Aug 25, 2026
Star Combo Pharma Ltd. has announced a dividend distribution to holders of its ordinary fully paid shares, signalling a return of capital to shareholders following the twelve-month period ending 30 June 2026. The payment, set at AUD 0.00296114 per...
Star Combo Pharma Files FY2026 Preliminary Final Report
Aug 25, 2026
Star Combo Pharma Ltd has released its Appendix 4E Preliminary Final Report for the financial year ended 30 June 2026, providing investors with an overview of its annual performance. The report package includes the directors’ report, full fi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.